Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4503 On Other Exchanges
Symbol
Exchange
4503 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

astellas pharma inc (4503) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ASTELLAS PHARMA INC (4503)

Related News

No related news articles were found.

astellas pharma inc (4503) Related Businessweek News

View More BusinessWeek News

astellas pharma inc (4503) Details

Astellas Pharma Inc. manufactures, markets, and imports/exports pharmaceutical products worldwide. The company focuses on the therapeutic areas of urology, immunology and infectious diseases, oncology, neuroscience, and diabetes mellitus complications and kidney diseases. The company offers immunosuppressants, including Prograf, and Advagraf/ Graceptor/ ASTAGRAF XL; Vesicare and Betanis/Myrbetriq/BETMIGA for overactive bladder treatment; and Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia. It also provides Funguard/MYCAMINE, a candin antifungal agent; Protopic for atopic dermatitis; Eligard, XTANDI, and Gonax for prostate cancer treatment; Micardis, including Micombi and Micamlo BP for hypertension; Celecox, an anti-inflammatory agent; Symbicort for adult bronchial asthma and chronic obstructive pulmonary disease; Geninax for oral quinolone antibiotic; Bonoteo for osteoporosis; Cimzia for the treatment of adult patients with rheumatoid arthritis; and Suglat for type two diabetes treatments. In addition, the company offers Lipitor products for the treatment of hypercholesterolemia; Gaster for peptic ulcers and gastritis; Myslee for insomnia; Seroquel for schizophrenia; Regnite for restless legs syndrome; Kiklin for hyperphatemia treatments, as well as Lexiscan and Adenoscan, which are pharmacologic stress agents; and Tarceva for the treatment of lung and pancreatic cancers. Further, it provides Acofide for functional dyspepsia; Bisono Tape, a transdermal hypertension medication; diarrhea-predominant OD tablets; and dificlir for clostridium difficile infections. It has a strategic alliance with Amgen Inc. and ClearPath Development Company; and collaborative agreements with Immuno-Biological Laboratories Co., Ltd., Cytokinetics, Inc., Mitokyne, Inc., QIAGEN N.V., Dana-Farber Cancer Institute, and Ventana Medical Systems, Inc. The company was founded in 1923 and is headquartered in Tokyo, Japan.

17,649 Employees
Last Reported Date: 06/18/14
Founded in 1923

astellas pharma inc (4503) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥170.0M
Compensation as of Fiscal Year 2014.

astellas pharma inc (4503) Key Developments

Astellas Pharma Receives Health Canada's Approval for New Indication for Xtandi (enzalutamide)

Astellas Pharma (Japan) has received Health Canada's approval for a new indication for Xtandi (enzalutamide) to treat patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failing androgen deprivation therapy (ADT). The Supplemental New Drug Submission was granted priority review by the Canadian agency. The approval was based on favourable results from the randomised, placebo-controlled, multinational Phase III PREVAIL study. The trial enrolled 1,717 chemotherapy-naïve patients with progressive mCRPC who had failed ADT and demonstrated a significant improvement in overall survival and prolonged time with enzalutamide therapy before radiographic progression or death compared with placebo. The study demonstrated an 81% reduction in risk of radiographic progression or death compared with placebo.

Ventana Medical Systems, Inc. Enters into Master Collaboration Agreement with Astellas Pharma Inc

Ventana Medical Systems, Inc. announced it has entered into master collaboration agreement with Astellas Pharma Inc. to develop novel automated tissue diagnostics in support of therapeutic compounds in development. Initial projects related to this agreement will support early-stage clinical trials for the Astellas therapeutic compound ASP5878, a novel small-molecule fibroblast growth factor receptor (FGFR) inhibitor which has been shown to block the kinase activities of FGFR1, FGFR2, FGFR3 and FGFR4. Ventana will develop, in parallel, an immunohistochemistry (IHC) test identifying FGF19 in certain solid tumors.

Astellas Pharma, Inc. Appoints Shontelle Dodson as Vice President, Medical Excellence, Medical Affairs

Astellas Pharma, Inc. announced that Dr. Shontelle Dodson has been named vice president, Medical Excellence, Medical Affairs. Dodson will be located at Astellas' global headquarters for its Medical and Development functions in Northbrook, Ill., USA, and will report to Dr. Charlotte Kremer, executive vice president, Medical Affairs. Dodson will oversee the Medical Excellence functions within the company's Medical Affairs organization, including Global Medical Communications, Scientific Publications, Health Economics and Outcomes Research, and Medical Affairs Research and Grants. As a key direct report to Kremer, she will play an instrumental role in leading key functional groups that provide support and service across the therapeutic areas served by the company's Medical Affairs organization.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4503:JP ¥1,896.50 JPY -19.50

4503 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.91 USD -0.24
Becton Dickinson and Co $141.53 USD -0.86
Boston Scientific Corp $18.40 USD +0.24
CSL Ltd A$94.06 AUD -0.77
Mylan NV $69.82 USD +2.98
View Industry Companies
 

Industry Analysis

4503

Industry Average

Valuation 4503 Industry Range
Price/Earnings 34.1x
Price/Sales 3.5x
Price/Book 3.1x
Price/Cash Flow 22.9x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC, please visit www.astellas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.